N-[4-[(7-chloroquinolin-4-yl)amino]butyl]naphthalene-2-sulfonamide | 1045718-04-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-[4-[(7-chloroquinolin-4-yl)amino]butyl]naphthalene-2-sulfonamide
• CAS: 1045718-04-4
• 化学式: C₂₃H₂₂ClN₃O₂S
• 分子量: 439.966
• InChiKey: LOMXLCLJLKVZRK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  30
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  79.5
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  溴甲苯 、 N-[4-[(7-chloroquinolin-4-yl)amino]butyl]naphthalene-2-sulfonamide 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 N-benzyl-N-[4-[(7-chloroquinolin-4-yl)amino]butyl]naphthalene-2-sulfonamide
  参考文献：
  名称：

  Modulation of human mammary cell sensitivity to paclitaxel by new quinoline sulfonamides

  摘要：

  Sulfonamide derivatives of chloroquine and primaquine were synthesised and evaluated against both paclitaxel-sensitive and paclitaxel-resistant mammarian cancer cell lines. All derivatives exhibited at least 96% MDR reversal activity when coadministered with paclitaxel at 5 muM. The best compound, a chloroquine derivative, exhibited 99% MDR reversal activity when coadministered with paclitaxel at 1 muM. Molecular modelling studies reveal that these derivatives share a common pharmacophore with taxane MDR reversal agents. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00462-0
• 作为产物：
  描述：

  4,7-二氯喹啉 在 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 N-[4-[(7-chloroquinolin-4-yl)amino]butyl]naphthalene-2-sulfonamide
  参考文献：
  名称：

  Modulation of human mammary cell sensitivity to paclitaxel by new quinoline sulfonamides

  摘要：

  Sulfonamide derivatives of chloroquine and primaquine were synthesised and evaluated against both paclitaxel-sensitive and paclitaxel-resistant mammarian cancer cell lines. All derivatives exhibited at least 96% MDR reversal activity when coadministered with paclitaxel at 5 muM. The best compound, a chloroquine derivative, exhibited 99% MDR reversal activity when coadministered with paclitaxel at 1 muM. Molecular modelling studies reveal that these derivatives share a common pharmacophore with taxane MDR reversal agents. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00462-0

文献信息

• Modulation of human mammary cell sensitivity to paclitaxel by new quinoline sulfonamides
  作者：Kelly Chibale、Iwao Ojima、Hayley Haupt、Xugong Geng、Paula Pera、Ralph J Bernacki

  DOI：10.1016/s0960-894x(01)00462-0

  日期：2001.9

  Sulfonamide derivatives of chloroquine and primaquine were synthesised and evaluated against both paclitaxel-sensitive and paclitaxel-resistant mammarian cancer cell lines. All derivatives exhibited at least 96% MDR reversal activity when coadministered with paclitaxel at 5 muM. The best compound, a chloroquine derivative, exhibited 99% MDR reversal activity when coadministered with paclitaxel at 1 muM. Molecular modelling studies reveal that these derivatives share a common pharmacophore with taxane MDR reversal agents. (C) 2001 Elsevier Science Ltd. All rights reserved.